ARROW

Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone (ARROW)

Status

Recruiting

JCP

Arrow

NCT

NCT03939689

C3441021 | TALAPRO-2

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

Status

Recruiting

JCP

JCP061

NCT

NCT03395197

CAPTUR | PM.1

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | A Phase II Basket Trial

Status

Recruiting

JCP

PM.1

NCT

NCT03297606

GURC | 212082PCR4049

A Study of Participants With Advanced Prostate Cancer in Canada (GURC)

Status

Recruiting

JCP

JCP048

NCT

NCT03501173

IND223

A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer

Status

Recruiting

JCP

IND223

NCT

NCT02905318

IND234

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Status

Recruiting

JCP

IND234

NCT

NCT03385655

SPLASH

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Status

Recruiting

JCP

JCP097

NCT

NCT04647526

3TMPO

Triple-tracer Molecular Imaging Using 18F-FDG, 68Ga-PSMA and 68Ga-OCTREOTATE to Characterize Metastatic Castration-resistant Prostate Cancer (mCRPC) and Evaluate Eligibility for Radionuclide Therapies

Status

Opening Soon

JCP

JCP093

NCT

NCT04000776

ARCHES | 9785-CL-0335

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (ARCHES)

Status

Closed to Accrual

JCP

JCP011

NCT

NCT02677896

CO39303

Ipatasertib Plus Abiraterone Plus Prednisone / Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone / Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150)

Status

Closed to Accrual

JCP

JCP022

NCT

NCT03072238

PSMA-617-01

Study of 177Lu-PSMA-617 in Metastatic Castrate-Resistant Prostate Cancer (VISION)

Status

Closed to Accrual

JCP

PSMA-617-01

NCT

NCT03511664